Navigation Links
Qnexa® Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment
Date:11/3/2011

and completion of clinical trials and submissions to the FDA or foreign authorities; the volatility and liquidity of the financial markets; our liquidity and capital resources; and our expected future revenues, operations and expenditures. As with any pharmaceutical in development, there are significant risks in the development, the regulatory approval, and commercialization of new products. There are no guarantees that our response to the FDA's CRL or the results of the retrospective observational study of fetal outcomes in infants born to mothers exposed to topiramate during pregnancy and subsequent meetings and communications will be sufficient to satisfy the FDA's safety concerns, that the FDA will not require us to conduct any additional prospective studies or retrospective observational studies, or that any product will receive regulatory approval for any indication or prove to be commercially successful. VIVUS does not undertake an obligation to update or revise any forward-looking statements. Investors should read the risk factors set forth in VIVUS' Form 10-K for the year ending December 31, 2010, and periodic reports filed with the Securities and Exchange Commission.

CONTACT: VIVUS, Inc. Media Relations:GolinHarris Timothy E. MorrisSusan Brophy Chief Financial Officersbrophy@golinharris.com 650-934-5200312-729-4359Investor Relations:The Trout GroupBrian Korbbkorb@troutgroup.com646-378-2923
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Multiple Presentations Featuring QNEXA® Data to be Presented at the European Congress on Obesity
2. QNEXA® Phase 3 Data in The Lancet Show Significant Weight Loss and Broad Improvements in Co-Morbidities
3. Weight Loss With QNEXA® Over Two Years Provides Patients With Substantial Cardiovascular Benefits
4. Long-Term Data on QNEXA® to be Presented at The American College of Cardiology Annual Meeting
5. VIVUS Submits Briefing Document to FDA, Announces Follow-up Meeting to Discuss QNEXA®
6. FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA®
7. New Long-Term Data on QNEXA® Show Significant and Sustained Weight Loss of Greater Than 10% Over Two Years
8. Isis Initiates Phase 1 Studies with Isis-GCGRRx and Isis-GCCRRx to Treat Type 2 Diabetes
9. Pharmasset Announces the Initiation of an Interferon-Free Phase 3 Program with PSI-7977 for HCV
10. Inovio Pharmaceuticals Cervical Dysplasia And Cancer Treatment Highlighted as One of 10 Promising Therapeutic Vaccines; Phase II Clinical Study Currently Enrolling
11. Cytogel Pharma, LLC. Announces Presentation at the American Society of Anesthesiologists meeting in Chicago on October 18, 2011, Describing Results From its First Human Study, Part of the Phase I Program for Cyt-1010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 2014  Sage Analytics ( www.sageanalytics.com ), the ... the testing of marijuana potency and moisture content, ... Profiler, the industry,s first product suite capable of ... portable unit. Designed from the ground ... cannabis industry, the Luminary™ Profiler utilizes specially purposed ...
(Date:12/19/2014)... Ky. , Dec. 18, 2014 Baptist Health ... States to receive full Atrial Fibrillation with Electrophysiology ... Care (SCPC). Atrial fibrillation is the most common ... that in some cases can lead to stroke and possible ... United States have atrial fibrillation and the numbers ...
(Date:12/19/2014)... robust development with the growth pace keeping at 20%-30% in ... the size of China separating membrane ... to 16.3%. It is projected that China ... around 20% in the upcoming years and that the figure ... An integrated membrane industrial system has taken shape in ...
Breaking Medicine Technology:Sage Analytics Develops Breakthrough System for Potency Testing of Cannabis Products 2Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 2Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 3Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 2Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 3
... 16, the U.S. Supreme Court will hear arguments in an ... v. SmithKline Beecham Corp. The specific question in the ... overtime pay. The larger issue is the deference that is ... statute. The Fair Labor Standards Act and ...
... April 10, 2012 Mylan Inc. (Nasdaq: MYL ... and live webcast on Thursday, April 26, 2012, at 10:00 ... first quarter 2012, which ended March 31, 2012. Mylan will ... opens. The dial-in number to access the call ...
Cached Medicine Technology:Supreme Court to Decide Overtime Fate for Pharmaceutical "Sales Representatives" -- JacksonWhite, Kingsley & Kingsley and Sanford Wittels & Heisler 2Supreme Court to Decide Overtime Fate for Pharmaceutical "Sales Representatives" -- JacksonWhite, Kingsley & Kingsley and Sanford Wittels & Heisler 3
(Date:12/19/2014)... Dec. 18, 2014 (HealthDay News) -- Traveling through the ... measles virus to three others within a four-hour time ... a new report shows. "The exposures in this ... rather than an international terminal, highlighting the fact that ... Jared Vega, an infectious disease specialist at the U.S. ...
(Date:12/19/2014)... HealthDay Reporter THURSDAY, Dec. 18, 2014 ... for at least 20 seconds you may be at risk ... one leg may indicate that small strokes or tiny bleeds ... strokes is high, the investigators reported online Dec. 18 in ... standing on one leg, as well as problems walking, should ...
(Date:12/17/2014)... 2014 Dr. Myo Nwe is the co-author ... of the Future” and co-founder of the Ace Medical Weight ... Nwe takes a broad look at the industry of weight ... scientific scrutiny. On film and in television shows, however, she ... the social aspects and played for basic laughs, which she ...
(Date:12/17/2014)... RI (PRWEB) December 17, 2014 ... recognize private practices that have made outstanding and ... in support and progression of private practice physical ... American Physical Therapy Association. , On behalf of ... OCS, owner and CEO of Performance accepted the ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 A group of ... for Longevity, today, in reaction to a recent statement by ... of brain training and derogated the efficacy of all brain ... agreed with the parts of the center’s statement critical of ... the center had also overstated its case, in a document ...
Breaking Medicine News(10 mins):Health News:Arriving Now at Gate 42: Measles 2Health News:Arriving Now at Gate 42: Measles 3Health News:Can You Balance on One Leg? You May Have Lower Stroke Risk 2Health News:Obesity Should Not Be a Hollywood Punchline, Weight Loss Doc Says 2Health News:Performance Physical Therapy Awarded with Jayne L. Snyder Private Practice of the Year 2014 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 3Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 4
... WASHINGTON, Sept. 16 The Amputee Coalition of America and ... Tom Harkin and Olympia J. Snowe and Representatives Robert E. ... joint organizations, 2009 Legislative Appreciation Awards. , , ... http://www.prnewswire.com/mnr/aopa/40117/ , , (Photo: ...
... , , Prostate ... , DENVER, Sept. 16 This September, the Prostate ... take lifesaving measures. In just 10 minutes, the same amount ... screened for prostate cancer, the second leading cause of death among ...
... , , , NORWALK, ... theft protection services, today announced the availability of new features in its ... damaging types of identity theft: medical identity theft. , , ... if personal health records containing inaccurate information are used by health care ...
... WASHINGTON, Sept. 16 While research shows many American children become ... is reversing the trend by motivating them to be more physically ... To view the Multimedia News Release, go to: http://www.prnewswire.com/mnr/ccna/39748/ ... launched in 2005 by Boys & Girls Clubs of America (BGCA) ...
... , , PITTSBURGH, Sept. 16 Mylan ... privately held Indian subsidiary, Matrix Laboratories Limited, has received tentative ... the President,s Emergency Plan for AIDS Relief (PEPFAR) for its ... Fumarate Tablets, 600 mg/300 mg/300 mg. , , ...
... , , , ... business of beauty and there was nothing more beautiful at the ... donated by designers such as Giorgio Armani, Tadashi and Luca Luca. ... and even created a Limited Edition Clarisonic just for the occasion. ...
Cached Medicine News:Health News:Video: Members of Congress Receive Legislative Awards From National Amputee Organizations 2Health News:Video: Members of Congress Receive Legislative Awards From National Amputee Organizations 3Health News:Free Screenings During Prostate Cancer Awareness Week 2Health News:Free Screenings During Prostate Cancer Awareness Week 3Health News:Affinion Security Center Launches Benefits to Help Detect and Resolve Medical Identity Theft 2Health News:Affinion Security Center Launches Benefits to Help Detect and Resolve Medical Identity Theft 3Health News:Video: Teen Girls Less Active, but Triple Play Program Bucks Trend 2Health News:Video: Teen Girls Less Active, but Triple Play Program Bucks Trend 3Health News:Video: Teen Girls Less Active, but Triple Play Program Bucks Trend 4Health News:Mylan's Matrix Receives Tentative FDA Approval Under PEPFAR for Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate Tablets 2Health News:Brooke Burke Debuts Limited Edition 'Couture' Clarisonic on Ultimate Style Stage: The SGK Pink Dress Runway at New York Fashion Week 2Health News:Brooke Burke Debuts Limited Edition 'Couture' Clarisonic on Ultimate Style Stage: The SGK Pink Dress Runway at New York Fashion Week 3
Bruns (Volkmann) bone curette, with Novotex plastic handle (autoclavable in autoclave up to 143C by 3 bar), 9, oval....
15" overall length, 9" handle....
9.5" overall length, 4.5" handle....
...
Medicine Products: